This page shows the latest chronic cough news and features for those working in and with pharma, biotech and healthcare.
Menlo Therapeutics has said its phase 2 trial of serlopitant in chronic itching (pruritus) is a bust, blaming the result on a high placebo response rate. ... like rival Vanda Therapeutics did with its rival NK1 drug tradipitant this week – as well as
has been pursued for the treatment of chronic cough.
MK-7264 reduces coughs per hour by 37%. Merck &Co's purchase of Afferent Pharma last year was all about a candidate drug for chronic cough - so it will be celebrating ... P2X3 receptors are thought to become over-activated in chronic cough, playing a
Merck &Co has agreed a deal to buy California biopharma company Afferent Pharma, adding a drug candidate for chronic cough to its pipeline. ... In a statement Merck's R&F head Roger Perlmutter said chronic cough represents "an area of significant unmet
It takes the form of a progressive scarring of the lungs, leading to shortness of breath, cough and - in extreme cases - can lead to fatal complications such as heart failure. ... Genoa Pharmaceuticals has an inhaled version of pirfenidone in phase III
For example, clinical trials are now underway in Manchester to see whether an AZ drug designed originally to treat gastro-oesophageal reflux disease can be used to treat chronic cough.
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
AF-219, a selective, non-narcotic, oral P2X3 antagonist, is currently in a phase 2b trial for the treatment of refractory, chronic cough and in a phase 2 trial in idiopathic ... licence, collaboration. 2, 560. Afferent Pharmaceuticals/ Merck &Co. AF-219,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...